SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '5vcx'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1IEP_B_STIB202_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	6 / 12	LEU A 116 VAL A 124 ALA A 137 GLU A 157 THR A 187 GLY A 191	H8H A 401 (-3.7A) H8H A 401 (-4.7A) H8H A 401 (-3.3A) None H8H A 401 (-3.5A) H8H A 401 (-4.4A)	0.84A	1iepB-5vcxA: 18.1	1iepB-5vcxA: 23.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1M17_A_AQ4A999_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	7 / 12	LEU A 116 ALA A 137 GLU A 157 LEU A 185 THR A 187 LEU A 189 ASP A 251	H8H A 401 (-3.7A) H8H A 401 (-3.3A) None H8H A 401 (-4.3A) H8H A 401 (-3.5A) None EDO A 402 ( 2.9A)	0.75A	1m17A-5vcxA: 24.5	1m17A-5vcxA: 22.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1M17_A_AQ4A999_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	7 / 12	LEU A 116 ALA A 137 LYS A 139 GLU A 157 LEU A 185 THR A 187 LEU A 189	H8H A 401 (-3.7A) H8H A 401 (-3.3A) H8H A 401 (-4.9A) None H8H A 401 (-4.3A) H8H A 401 (-3.5A) None	0.89A	1m17A-5vcxA: 24.5	1m17A-5vcxA: 22.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1OPJ_B_STIB4_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	6 / 12	VAL A 124 ALA A 137 GLU A 157 VAL A 171 THR A 187 GLY A 191	H8H A 401 (-4.7A) H8H A 401 (-3.3A) None None H8H A 401 (-3.5A) H8H A 401 (-4.4A)	0.90A	1opjB-5vcxA: 17.6	1opjB-5vcxA: 23.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	7 / 12	ALA A 137 GLU A 157 THR A 187 CYH A 190 LEU A 224 HIS A 231 GLY A 250	H8H A 401 (-3.3A) None H8H A 401 (-3.5A) H8H A 401 (-4.3A) None None None	0.65A	1uwhA-5vcxA: 22.7	1uwhA-5vcxA: 24.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	6 / 12	ALA A 137 THR A 187 LEU A 224 HIS A 231 GLY A 250 PHE A 240	H8H A 401 (-3.3A) H8H A 401 (-3.5A) None None None H8H A 401 (-4.3A)	1.33A	1uwhA-5vcxA: 22.7	1uwhA-5vcxA: 24.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	7 / 12	ALA A 137 GLU A 157 THR A 187 CYH A 190 LEU A 224 HIS A 231 GLY A 250	H8H A 401 (-3.3A) None H8H A 401 (-3.5A) H8H A 401 (-4.3A) None None None	0.65A	1uwhB-5vcxA: 22.6	1uwhB-5vcxA: 24.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWJ_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	8 / 12	VAL A 124 ALA A 137 GLU A 157 THR A 187 CYH A 190 LEU A 224 HIS A 231 GLY A 250	H8H A 401 (-4.7A) H8H A 401 (-3.3A) None H8H A 401 (-3.5A) H8H A 401 (-4.3A) None None None	0.66A	1uwjA-5vcxA: 6.9	1uwjA-5vcxA: 24.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWJ_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	8 / 12	VAL A 124 ALA A 137 GLU A 157 THR A 187 CYH A 190 LEU A 224 HIS A 231 GLY A 250	H8H A 401 (-4.7A) H8H A 401 (-3.3A) None H8H A 401 (-3.5A) H8H A 401 (-4.3A) None None None	0.66A	1uwjB-5vcxA: 5.6	1uwjB-5vcxA: 24.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XKK_A_FMMA91_2 (EPIDERMAL GROWTH FACTOR RECEPTOR)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	5 / 9	LEU A 116 VAL A 124 LEU A 173 LEU A 185 LEU A 189	H8H A 401 (-3.7A) H8H A 401 (-4.7A) None H8H A 401 (-4.3A) None	0.76A	1xkkA-5vcxA: 22.7	1xkkA-5vcxA: 25.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2EJF_A_ADNA2001_1 (235AA LONG HYPOTHETICAL BIOTIN--[ACETYL-COA- CARBOXYLASE] LIGASE)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	4 / 7	ARG A 316 ALA A 287 PRO A 344 ALA A 286	None	1.07A	2ejfA-5vcxA: undetectable	2ejfA-5vcxA: 23.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2FUM_A_MIXA539_1 (PROBABLE SERINE/THREONINE-PRO TEIN KINASE PKNB)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	8 / 12	LEU A 116 VAL A 124 ALA A 137 ASP A 233 LYS A 235 ALA A 237 ASN A 238 ASP A 251	H8H A 401 (-3.7A) H8H A 401 (-4.7A) H8H A 401 (-3.3A) None EDO A 402 (-3.4A) H8H A 401 ( 4.4A) EDO A 402 (-3.9A) EDO A 402 ( 2.9A)	0.87A	2fumA-5vcxA: 20.8	2fumA-5vcxA: 28.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ZLC_A_VDXA500_1 (VITAMIN D3 RECEPTOR)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	5 / 12	LEU A 336 VAL A 335 SER A 329 CYH A 301 LEU A 354	None	1.24A	2zlcA-5vcxA: undetectable	2zlcA-5vcxA: 22.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3BBT_B_FMMB91_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	8 / 12	VAL A 124 ALA A 137 LEU A 173 THR A 187 LEU A 189 GLY A 191 ASP A 251 PHE A 252	H8H A 401 (-4.7A) H8H A 401 (-3.3A) None H8H A 401 (-3.5A) None H8H A 401 (-4.4A) EDO A 402 ( 2.9A) None	1.29A	3bbtB-5vcxA: 17.3	3bbtB-5vcxA: 23.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3FL9_B_TOPB200_1 (DIHYDROFOLATE REDUCTASE (DHFR))	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	5 / 12	MET A 338 LEU A 218 LEU A 359 ILE A 296 LEU A 332	None	1.04A	3fl9B-5vcxA: undetectable	3fl9B-5vcxA: 19.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3FL9_E_TOPE200_1 (DIHYDROFOLATE REDUCTASE (DHFR))	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	5 / 10	MET A 338 LEU A 218 LEU A 359 ILE A 296 LEU A 332	None	1.05A	3fl9E-5vcxA: undetectable	3fl9E-5vcxA: 19.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3FL9_G_TOPG200_1 (DIHYDROFOLATE REDUCTASE (DHFR))	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	5 / 12	MET A 338 LEU A 218 LEU A 359 ILE A 296 LEU A 332	None	1.12A	3fl9G-5vcxA: undetectable	3fl9G-5vcxA: 19.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3GVU_A_STIA1001_1 (TYROSINE-PROTEIN KINASE ABL2)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	6 / 12	LEU A 116 VAL A 124 ALA A 137 GLU A 157 VAL A 171 THR A 187	H8H A 401 (-3.7A) H8H A 401 (-4.7A) H8H A 401 (-3.3A) None None H8H A 401 (-3.5A)	0.55A	3gvuA-5vcxA: 18.3	3gvuA-5vcxA: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3HEC_A_STIA1_1 (MITOGEN-ACTIVATED PROTEIN KINASE 14)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	5 / 12	ALA A 137 LYS A 139 GLU A 157 THR A 187 LEU A 189	H8H A 401 (-3.3A) H8H A 401 (-4.9A) None H8H A 401 (-3.5A) None	0.79A	3hecA-5vcxA: 18.1	3hecA-5vcxA: 24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3HM1_B_J3ZB1_1 (ESTROGEN RECEPTOR)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	5 / 11	LEU A 232 LEU A 254 GLY A 228 HIS A 225 LEU A 224	None	1.27A	3hm1B-5vcxA: undetectable	3hm1B-5vcxA: 22.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3LFA_A_1N1A361_1 (MITOGEN-ACTIVATED PROTEIN KINASE 14)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	5 / 8	ALA A 137 LYS A 139 GLU A 157 LEU A 185 LEU A 189	H8H A 401 (-3.3A) H8H A 401 (-4.9A) None H8H A 401 (-4.3A) None	1.07A	3lfaA-5vcxA: 22.1	3lfaA-5vcxA: 23.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3LFA_A_1N1A361_1 (MITOGEN-ACTIVATED PROTEIN KINASE 14)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	5 / 8	ALA A 137 LYS A 139 GLU A 157 THR A 187 LEU A 189	H8H A 401 (-3.3A) H8H A 401 (-4.9A) None H8H A 401 (-3.5A) None	0.83A	3lfaA-5vcxA: 22.1	3lfaA-5vcxA: 23.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OG7_A_032A1_1 (AKAP9-BRAF FUSION PROTEIN)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	6 / 12	VAL A 124 ALA A 137 LYS A 139 THR A 187 CYH A 190 GLY A 253	H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-4.9A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) None	1.13A	3og7A-5vcxA: 18.1	3og7A-5vcxA: 25.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OG7_A_032A1_1 (AKAP9-BRAF FUSION PROTEIN)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	6 / 12	VAL A 124 ALA A 137 THR A 187 CYH A 190 PHE A 240 GLY A 253	H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) H8H A 401 (-4.3A) None	0.67A	3og7A-5vcxA: 18.1	3og7A-5vcxA: 25.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OG7_A_032A1_1 (AKAP9-BRAF FUSION PROTEIN)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	6 / 12	VAL A 124 ALA A 137 THR A 187 CYH A 190 PHE A 240 PHE A 252	H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) H8H A 401 (-4.3A) None	0.83A	3og7A-5vcxA: 18.1	3og7A-5vcxA: 25.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OHT_B_1N1B1000_1 (P38A)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	5 / 12	GLY A 117 VAL A 124 ALA A 137 LYS A 139 THR A 187	H8H A 401 ( 3.7A) H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-4.9A) H8H A 401 (-3.5A)	0.49A	3ohtB-5vcxA: 18.0	3ohtB-5vcxA: 24.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3PYY_A_STIA3_1 (V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	6 / 12	LEU A 116 VAL A 124 ALA A 137 GLU A 157 THR A 187 GLY A 191	H8H A 401 (-3.7A) H8H A 401 (-4.7A) H8H A 401 (-3.3A) None H8H A 401 (-3.5A) H8H A 401 (-4.4A)	0.75A	3pyyA-5vcxA: 18.1	3pyyA-5vcxA: 26.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3PYY_B_STIB4_1 (V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	6 / 12	LEU A 116 VAL A 124 ALA A 137 GLU A 157 VAL A 171 THR A 187	H8H A 401 (-3.7A) H8H A 401 (-4.7A) H8H A 401 (-3.3A) None None H8H A 401 (-3.5A)	0.61A	3pyyB-5vcxA: 18.0	3pyyB-5vcxA: 26.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXO_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	8 / 12	LEU A 116 VAL A 124 ALA A 137 LYS A 139 GLU A 157 VAL A 171 THR A 187 ASP A 251	H8H A 401 (-3.7A) H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-4.9A) None None H8H A 401 (-3.5A) EDO A 402 ( 2.9A)	0.85A	4mxoA-5vcxA: 19.7	4mxoA-5vcxA: 26.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4R7I_A_STIA1001_1 (MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	6 / 12	VAL A 124 ALA A 137 GLU A 157 THR A 187 CYH A 190 GLY A 250	H8H A 401 (-4.7A) H8H A 401 (-3.3A) None H8H A 401 (-3.5A) H8H A 401 (-4.3A) None	0.60A	4r7iA-5vcxA: 22.7	4r7iA-5vcxA: 28.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZV_A_032A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	6 / 12	ALA A 137 THR A 187 SER A 193 PHE A 240 GLY A 250 GLY A 253	H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 ( 4.4A) H8H A 401 (-4.3A) None None	1.11A	4rzvA-5vcxA: 5.4	4rzvA-5vcxA: 26.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZV_A_032A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	6 / 12	ALA A 137 THR A 187 SER A 193 PHE A 240 GLY A 250 PHE A 252	H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 ( 4.4A) H8H A 401 (-4.3A) None None	0.78A	4rzvA-5vcxA: 5.4	4rzvA-5vcxA: 26.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZV_B_032B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	7 / 12	ALA A 137 THR A 187 CYH A 190 SER A 193 PHE A 240 GLY A 250 GLY A 253	H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) H8H A 401 ( 4.4A) H8H A 401 (-4.3A) None None	1.17A	4rzvB-5vcxA: 17.4	4rzvB-5vcxA: 26.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZV_B_032B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	7 / 12	ALA A 137 THR A 187 CYH A 190 SER A 193 PHE A 240 GLY A 250 PHE A 252	H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) H8H A 401 ( 4.4A) H8H A 401 (-4.3A) None None	0.88A	4rzvB-5vcxA: 17.4	4rzvB-5vcxA: 26.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZV_B_032B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	6 / 12	VAL A 124 ALA A 137 LYS A 139 THR A 187 CYH A 190 GLY A 253	H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-4.9A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) None	1.11A	4rzvB-5vcxA: 17.4	4rzvB-5vcxA: 26.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZV_B_032B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	7 / 12	VAL A 124 ALA A 137 THR A 187 CYH A 190 SER A 193 PHE A 240 GLY A 253	H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) H8H A 401 ( 4.4A) H8H A 401 (-4.3A) None	0.96A	4rzvB-5vcxA: 17.4	4rzvB-5vcxA: 26.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZV_B_032B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	7 / 12	VAL A 124 ALA A 137 THR A 187 CYH A 190 SER A 193 PHE A 240 PHE A 252	H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) H8H A 401 ( 4.4A) H8H A 401 (-4.3A) None	0.91A	4rzvB-5vcxA: 17.4	4rzvB-5vcxA: 26.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4UXQ_A_0LIA1752_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	5 / 12	LEU A 116 ALA A 137 GLU A 157 LEU A 224 HIS A 231	H8H A 401 (-3.7A) H8H A 401 (-3.3A) None None None	0.59A	4uxqA-5vcxA: 22.9	4uxqA-5vcxA: 24.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XV2_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	7 / 12	VAL A 124 ALA A 137 THR A 187 CYH A 190 PHE A 240 GLY A 250 ASP A 251	H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) H8H A 401 (-4.3A) None EDO A 402 ( 2.9A)	0.76A	4xv2A-5vcxA: 18.5	4xv2A-5vcxA: 25.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XV2_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	7 / 12	VAL A 124 ALA A 137 THR A 187 PHE A 240 GLY A 250 ASP A 251 PHE A 252	H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) None EDO A 402 ( 2.9A) None	0.81A	4xv2A-5vcxA: 18.5	4xv2A-5vcxA: 25.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XV2_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	6 / 12	ALA A 137 THR A 187 CYH A 190 PHE A 240 GLY A 250 ASP A 251	H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) H8H A 401 (-4.3A) None EDO A 402 ( 2.9A)	0.67A	4xv2B-5vcxA: 22.6	4xv2B-5vcxA: 25.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XV2_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	6 / 12	ALA A 137 THR A 187 PHE A 240 GLY A 250 ASP A 251 PHE A 252	H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) None EDO A 402 ( 2.9A) None	0.65A	4xv2B-5vcxA: 22.6	4xv2B-5vcxA: 25.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	6 / 12	VAL A 124 ALA A 137 THR A 187 CYH A 190 PHE A 240 GLY A 250	H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) H8H A 401 (-4.3A) None	0.66A	5cswA-5vcxA: 22.0	5cswA-5vcxA: 24.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	6 / 12	VAL A 124 ALA A 137 THR A 187 PHE A 240 GLY A 250 PHE A 252	H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) None None	0.84A	5cswA-5vcxA: 22.0	5cswA-5vcxA: 24.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	6 / 12	VAL A 124 ALA A 137 THR A 187 CYH A 190 PHE A 240 GLY A 250	H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) H8H A 401 (-4.3A) None	0.63A	5cswB-5vcxA: 22.4	5cswB-5vcxA: 24.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	6 / 12	VAL A 124 ALA A 137 THR A 187 PHE A 240 GLY A 250 PHE A 252	H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) None None	0.83A	5cswB-5vcxA: 22.4	5cswB-5vcxA: 24.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_D_1N1D504_1 (PROTEIN-TYROSINE KINASE 6)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	7 / 12	LEU A 116 VAL A 124 ALA A 137 THR A 187 LEU A 189 GLY A 250 ASP A 251	H8H A 401 (-3.7A) H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-3.5A) None None EDO A 402 ( 2.9A)	0.65A	5h2uD-5vcxA: 17.1	5h2uD-5vcxA: 25.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HI2_A_BAXA801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	7 / 12	ALA A 137 GLU A 157 THR A 187 CYH A 190 LEU A 224 HIS A 231 GLY A 250	H8H A 401 (-3.3A) None H8H A 401 (-3.5A) H8H A 401 (-4.3A) None None None	0.71A	5hi2A-5vcxA: 22.3	5hi2A-5vcxA: 26.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HI2_A_BAXA801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	7 / 12	ALA A 137 LYS A 139 GLU A 157 THR A 187 CYH A 190 HIS A 231 GLY A 250	H8H A 401 (-3.3A) H8H A 401 (-4.9A) None H8H A 401 (-3.5A) H8H A 401 (-4.3A) None None	0.80A	5hi2A-5vcxA: 22.3	5hi2A-5vcxA: 26.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	5 / 12	VAL A 124 ALA A 137 THR A 187 PHE A 240 GLY A 250	H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) None	0.64A	5hieA-5vcxA: 7.0	5hieA-5vcxA: 27.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	5 / 12	VAL A 124 ALA A 137 THR A 187 PHE A 240 GLY A 250	H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) None	0.66A	5hieB-5vcxA: 6.9	5hieB-5vcxA: 27.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_C_P06C801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	6 / 12	GLY A 117 VAL A 124 ALA A 137 THR A 187 PHE A 240 GLY A 250	H8H A 401 ( 3.7A) H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) None	0.75A	5hieC-5vcxA: 21.2	5hieC-5vcxA: 27.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_C_P06C801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	6 / 12	VAL A 124 ALA A 137 THR A 187 PHE A 240 GLY A 250 ASP A 251	H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) None EDO A 402 ( 2.9A)	0.81A	5hieC-5vcxA: 21.2	5hieC-5vcxA: 27.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_D_P06D801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	5 / 12	VAL A 124 ALA A 137 THR A 187 PHE A 240 GLY A 250	H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) None	0.65A	5hieD-5vcxA: 21.0	5hieD-5vcxA: 27.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5IZJ_G_AZ1G2_1 (CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA 47P-AZ1-DAR-DAR)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	5 / 7	GLY A 117 GLY A 119 SER A 120 VAL A 124 LYS A 139	H8H A 401 ( 3.7A) None None H8H A 401 (-4.7A) H8H A 401 (-4.9A)	0.80A	5izjA-5vcxA: 24.3	5izjA-5vcxA: 26.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5J5X_B_AZ1B2_1 (CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA 47P-AZ1-DAL-DAR-DAR- DAR-DAR)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	5 / 7	GLY A 117 GLY A 119 SER A 120 VAL A 124 LYS A 139	H8H A 401 ( 3.7A) None None H8H A 401 (-4.7A) H8H A 401 (-4.9A)	0.66A	5j5xA-5vcxA: 24.1	5j5xA-5vcxA: 26.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5OWR_A_1N1A401_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	4 / 8	ALA A 137 GLU A 157 CYH A 190 ASP A 251	H8H A 401 (-3.3A) None H8H A 401 (-4.3A) EDO A 402 ( 2.9A)	0.53A	5owrA-5vcxA: 15.2	5owrA-5vcxA: 27.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5VC3_A_DB8A601_1 (WEE1-LIKE PROTEIN KINASE)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	6 / 12	ALA A 137 GLU A 157 CYH A 190 GLY A 191 PHE A 240 ASP A 251	H8H A 401 (-3.3A) None H8H A 401 (-4.3A) H8H A 401 (-4.4A) H8H A 401 (-4.3A) EDO A 402 ( 2.9A)	0.97A	5vc3A-5vcxA: 24.0	5vc3A-5vcxA: 32.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5VC3_A_DB8A601_2 (WEE1-LIKE PROTEIN KINASE)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	4 / 4	VAL A 124 LYS A 139 VAL A 171 ASN A 238	H8H A 401 (-4.7A) H8H A 401 (-4.9A) None EDO A 402 (-3.9A)	0.37A	5vc3A-5vcxA: 24.0	5vc3A-5vcxA: 32.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5VCV_A_1N1A404_1 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	12 / 12	LEU A 116 ALA A 137 LYS A 139 GLU A 157 VAL A 171 LEU A 185 THR A 187 GLY A 191 PRO A 192 GLN A 196 PHE A 240 GLY A 250	H8H A 401 (-3.7A) H8H A 401 (-3.3A) H8H A 401 (-4.9A) None None H8H A 401 (-4.3A) H8H A 401 (-3.5A) H8H A 401 (-4.4A) H8H A 401 ( 4.1A) H8H A 401 ( 4.4A) H8H A 401 (-4.3A) None	0.59A	5vcvA-5vcxA: 43.9	5vcvA-5vcxA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5VCV_A_1N1A404_2 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	5 / 5	VAL A 124 HIS A 161 LEU A 189 CYH A 190 ASP A 251	H8H A 401 (-4.7A) None None H8H A 401 (-4.3A) EDO A 402 ( 2.9A)	0.50A	5vcvA-5vcxA: 44.0	5vcvA-5vcxA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5VCY_A_DB8A401_1 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	12 / 12	LEU A 116 VAL A 124 ALA A 137 LYS A 139 GLU A 157 LEU A 185 THR A 187 CYH A 190 GLY A 191 PRO A 192 GLN A 196 PHE A 240	H8H A 401 (-3.7A) H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-4.9A) None H8H A 401 (-4.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) H8H A 401 (-4.4A) H8H A 401 ( 4.1A) H8H A 401 ( 4.4A) H8H A 401 (-4.3A)	0.53A	5vcyA-5vcxA: 42.4	5vcyA-5vcxA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5VCY_A_DB8A401_2 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	4 / 4	VAL A 171 LEU A 189 ASN A 238 ASP A 251	None None EDO A 402 (-3.9A) EDO A 402 ( 2.9A)	0.75A	5vcyA-5vcxA: 42.4	5vcyA-5vcxA: 100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y7Z_A_IREA401_0 (CYCLIN-G-ASSOCIATED KINASE)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	7 / 12	LEU A 116 VAL A 124 ALA A 137 LYS A 139 GLU A 157 LEU A 189 CYH A 190	H8H A 401 (-3.7A) H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-4.9A) None None H8H A 401 (-4.3A)	0.44A	5y7zA-5vcxA: 23.4	5y7zA-5vcxA: 14.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y7Z_A_IREA401_0 (CYCLIN-G-ASSOCIATED KINASE)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	7 / 12	LEU A 116 VAL A 124 ALA A 137 LYS A 139 GLU A 157 LEU A 189 CYH A 190	H8H A 401 (-3.7A) H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-4.9A) None None H8H A 401 (-4.3A)	0.44A	5y7zA-5vcxA: 23.4	5y7zA-5vcxA: 26.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y7Z_A_IREA401_0 (CYCLIN-G-ASSOCIATED KINASE)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	7 / 12	VAL A 124 ALA A 137 LYS A 139 GLU A 157 LEU A 189 CYH A 190 GLY A 191	H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-4.9A) None None H8H A 401 (-4.3A) H8H A 401 (-4.4A)	0.95A	5y7zA-5vcxA: 23.4	5y7zA-5vcxA: 14.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y7Z_A_IREA401_0 (CYCLIN-G-ASSOCIATED KINASE)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	7 / 12	VAL A 124 ALA A 137 LYS A 139 GLU A 157 LEU A 189 CYH A 190 GLY A 191	H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-4.9A) None None H8H A 401 (-4.3A) H8H A 401 (-4.4A)	0.95A	5y7zA-5vcxA: 23.4	5y7zA-5vcxA: 26.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y7Z_B_IREB401_0 (CYCLIN-G-ASSOCIATED KINASE)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	8 / 12	LEU A 116 ALA A 137 GLU A 157 LEU A 185 LEU A 189 CYH A 190 GLY A 191 ASP A 251	H8H A 401 (-3.7A) H8H A 401 (-3.3A) None H8H A 401 (-4.3A) None H8H A 401 (-4.3A) H8H A 401 (-4.4A) EDO A 402 ( 2.9A)	0.89A	5y7zB-5vcxA: 23.5	5y7zB-5vcxA: 14.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y7Z_B_IREB401_0 (CYCLIN-G-ASSOCIATED KINASE)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	8 / 12	LEU A 116 ALA A 137 LYS A 139 GLU A 157 LEU A 185 LEU A 189 CYH A 190 GLY A 191	H8H A 401 (-3.7A) H8H A 401 (-3.3A) H8H A 401 (-4.9A) None H8H A 401 (-4.3A) None H8H A 401 (-4.3A) H8H A 401 (-4.4A)	0.99A	5y7zB-5vcxA: 23.5	5y7zB-5vcxA: 14.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y80_A_IREA401_0 (CYCLIN-G-ASSOCIATED KINASE)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	9 / 12	LEU A 116 VAL A 124 ALA A 137 GLU A 157 THR A 187 LEU A 189 CYH A 190 GLY A 191 ASP A 251	H8H A 401 (-3.7A) H8H A 401 (-4.7A) H8H A 401 (-3.3A) None H8H A 401 (-3.5A) None H8H A 401 (-4.3A) H8H A 401 (-4.4A) EDO A 402 ( 2.9A)	0.82A	5y80A-5vcxA: 22.7	5y80A-5vcxA: 14.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y80_A_IREA401_0 (CYCLIN-G-ASSOCIATED KINASE)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	9 / 12	LEU A 116 VAL A 124 ALA A 137 LYS A 139 GLU A 157 THR A 187 LEU A 189 CYH A 190 GLY A 191	H8H A 401 (-3.7A) H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-4.9A) None H8H A 401 (-3.5A) None H8H A 401 (-4.3A) H8H A 401 (-4.4A)	0.93A	5y80A-5vcxA: 22.7	5y80A-5vcxA: 14.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YW0_A_ACTA411_0 (UNCHARACTERIZED PROTEIN KDOO)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	3 / 3	LYS A 126 LEU A 135 ARG A 128	None	0.88A	5yw0A-5vcxA: undetectable	5yw0A-5vcxA: 23.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD6_B_STIB601_0 (TYROSINE-PROTEIN KINASE ABL1)	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	7 / 12	LEU A 116 VAL A 124 ALA A 137 LYS A 139 GLU A 157 VAL A 171 THR A 187	H8H A 401 (-3.7A) H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-4.9A) None None H8H A 401 (-3.5A)	0.71A	6hd6B-5vcxA: 17.5	6hd6B-5vcxA: 13.27

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1IEP_B_STIB202_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",6,"LEU A 116;VAL A 124;ALA A 137;GLU A 157;THR A 187;GLY A 191","H8H A 401 (-3.7A);H8H A 401 (-4.7A);H8H A 401 (-3.3A);None;H8H A 401 (-3.5A);H8H A 401 (-4.4A)","0.84A","1iepB-5vcxA:18.1","1iepB-5vcxA:23.17"],["1M17_A_AQ4A999_1","EPIDERMAL GROWTH FACTOR RECEPTOR","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",7,"LEU A 116;ALA A 137;GLU A 157;LEU A 185;THR A 187;LEU A 189;ASP A 251","H8H A 401 (-3.7A);H8H A 401 (-3.3A);None;H8H A 401 (-4.3A);H8H A 401 (-3.5A);None;EDO A 402 ( 2.9A)","0.75A","1m17A-5vcxA:24.5","1m17A-5vcxA:22.46"],["1M17_A_AQ4A999_1","EPIDERMAL GROWTH FACTOR RECEPTOR","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",7,"LEU A 116;ALA A 137;LYS A 139;GLU A 157;LEU A 185;THR A 187;LEU A 189","H8H A 401 (-3.7A);H8H A 401 (-3.3A);H8H A 401 (-4.9A);None;H8H A 401 (-4.3A);H8H A 401 (-3.5A);None","0.89A","1m17A-5vcxA:24.5","1m17A-5vcxA:22.46"],["1OPJ_B_STIB4_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",6,"VAL A 124;ALA A 137;GLU A 157;VAL A 171;THR A 187;GLY A 191","H8H A 401 (-4.7A);H8H A 401 (-3.3A);None;None;H8H A 401 (-3.5A);H8H A 401 (-4.4A)","0.90A","1opjB-5vcxA:17.6","1opjB-5vcxA:23.17"],["1UWH_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",7,"ALA A 137;GLU A 157;THR A 187;CYH A 190;LEU A 224;HIS A 231;GLY A 250","H8H A 401 (-3.3A);None;H8H A 401 (-3.5A);H8H A 401 (-4.3A);None;None;None","0.65A","1uwhA-5vcxA:22.7","1uwhA-5vcxA:24.17"],["1UWH_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",6,"ALA A 137;THR A 187;LEU A 224;HIS A 231;GLY A 250;PHE A 240","H8H A 401 (-3.3A);H8H A 401 (-3.5A);None;None;None;H8H A 401 (-4.3A)","1.33A","1uwhA-5vcxA:22.7","1uwhA-5vcxA:24.17"],["1UWH_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",7,"ALA A 137;GLU A 157;THR A 187;CYH A 190;LEU A 224;HIS A 231;GLY A 250","H8H A 401 (-3.3A);None;H8H A 401 (-3.5A);H8H A 401 (-4.3A);None;None;None","0.65A","1uwhB-5vcxA:22.6","1uwhB-5vcxA:24.17"],["1UWJ_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",8,"VAL A 124;ALA A 137;GLU A 157;THR A 187;CYH A 190;LEU A 224;HIS A 231;GLY A 250","H8H A 401 (-4.7A);H8H A 401 (-3.3A);None;H8H A 401 (-3.5A);H8H A 401 (-4.3A);None;None;None","0.66A","1uwjA-5vcxA:6.9","1uwjA-5vcxA:24.17"],["1UWJ_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",8,"VAL A 124;ALA A 137;GLU A 157;THR A 187;CYH A 190;LEU A 224;HIS A 231;GLY A 250","H8H A 401 (-4.7A);H8H A 401 (-3.3A);None;H8H A 401 (-3.5A);H8H A 401 (-4.3A);None;None;None","0.66A","1uwjB-5vcxA:5.6","1uwjB-5vcxA:24.17"],["1XKK_A_FMMA91_2","EPIDERMAL GROWTH FACTOR RECEPTOR","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",5,"LEU A 116;VAL A 124;LEU A 173;LEU A 185;LEU A 189","H8H A 401 (-3.7A);H8H A 401 (-4.7A);None;H8H A 401 (-4.3A);None","0.76A","1xkkA-5vcxA:22.7","1xkkA-5vcxA:25.00"],["2EJF_A_ADNA2001_1","235AA LONG HYPOTHETICAL BIOTIN--[ACETYL-COA-CARBOXYLASE] LIGASE","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",4,"ARG A 316;ALA A 287;PRO A 344;ALA A 286","None","1.07A","2ejfA-5vcxA:undetectable","2ejfA-5vcxA:23.15"],["2FUM_A_MIXA539_1","PROBABLE SERINE\/THREONINE-PROTEIN KINASE PKNB","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",8,"LEU A 116;VAL A 124;ALA A 137;ASP A 233;LYS A 235;ALA A 237;ASN A 238;ASP A 251","H8H A 401 (-3.7A);H8H A 401 (-4.7A);H8H A 401 (-3.3A);None;EDO A 402 (-3.4A);H8H A 401 ( 4.4A);EDO A 402 (-3.9A);EDO A 402 ( 2.9A)","0.87A","2fumA-5vcxA:20.8","2fumA-5vcxA:28.61"],["2ZLC_A_VDXA500_1","VITAMIN D3 RECEPTOR","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",5,"LEU A 336;VAL A 335;SER A 329;CYH A 301;LEU A 354","None","1.24A","2zlcA-5vcxA:undetectable","2zlcA-5vcxA:22.45"],["3BBT_B_FMMB91_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",8,"VAL A 124;ALA A 137;LEU A 173;THR A 187;LEU A 189;GLY A 191;ASP A 251;PHE A 252","H8H A 401 (-4.7A);H8H A 401 (-3.3A);None;H8H A 401 (-3.5A);None;H8H A 401 (-4.4A);EDO A 402 ( 2.9A);None","1.29A","3bbtB-5vcxA:17.3","3bbtB-5vcxA:23.39"],["3FL9_B_TOPB200_1","DIHYDROFOLATE REDUCTASE (DHFR)","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",5,"MET A 338;LEU A 218;LEU A 359;ILE A 296;LEU A 332","None","1.04A","3fl9B-5vcxA:undetectable","3fl9B-5vcxA:19.11"],["3FL9_E_TOPE200_1","DIHYDROFOLATE REDUCTASE (DHFR)","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",5,"MET A 338;LEU A 218;LEU A 359;ILE A 296;LEU A 332","None","1.05A","3fl9E-5vcxA:undetectable","3fl9E-5vcxA:19.11"],["3FL9_G_TOPG200_1","DIHYDROFOLATE REDUCTASE (DHFR)","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",5,"MET A 338;LEU A 218;LEU A 359;ILE A 296;LEU A 332","None","1.12A","3fl9G-5vcxA:undetectable","3fl9G-5vcxA:19.11"],["3GVU_A_STIA1001_1","TYROSINE-PROTEIN KINASE ABL2","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",6,"LEU A 116;VAL A 124;ALA A 137;GLU A 157;VAL A 171;THR A 187","H8H A 401 (-3.7A);H8H A 401 (-4.7A);H8H A 401 (-3.3A);None;None;H8H A 401 (-3.5A)","0.55A","3gvuA-5vcxA:18.3","3gvuA-5vcxA:28.53"],["3HEC_A_STIA1_1","MITOGEN-ACTIVATED PROTEIN KINASE 14","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",5,"ALA A 137;LYS A 139;GLU A 157;THR A 187;LEU A 189","H8H A 401 (-3.3A);H8H A 401 (-4.9A);None;H8H A 401 (-3.5A);None","0.79A","3hecA-5vcxA:18.1","3hecA-5vcxA:24.24"],["3HM1_B_J3ZB1_1","ESTROGEN RECEPTOR","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",5,"LEU A 232;LEU A 254;GLY A 228;HIS A 225;LEU A 224","None","1.27A","3hm1B-5vcxA:undetectable","3hm1B-5vcxA:22.32"],["3LFA_A_1N1A361_1","MITOGEN-ACTIVATED PROTEIN KINASE 14","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",5,"ALA A 137;LYS A 139;GLU A 157;LEU A 185;LEU A 189","H8H A 401 (-3.3A);H8H A 401 (-4.9A);None;H8H A 401 (-4.3A);None","1.07A","3lfaA-5vcxA:22.1","3lfaA-5vcxA:23.58"],["3LFA_A_1N1A361_1","MITOGEN-ACTIVATED PROTEIN KINASE 14","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",5,"ALA A 137;LYS A 139;GLU A 157;THR A 187;LEU A 189","H8H A 401 (-3.3A);H8H A 401 (-4.9A);None;H8H A 401 (-3.5A);None","0.83A","3lfaA-5vcxA:22.1","3lfaA-5vcxA:23.58"],["3OG7_A_032A1_1","AKAP9-BRAF FUSION PROTEIN","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",6,"VAL A 124;ALA A 137;LYS A 139;THR A 187;CYH A 190;GLY A 253","H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-4.9A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);None","1.13A","3og7A-5vcxA:18.1","3og7A-5vcxA:25.72"],["3OG7_A_032A1_1","AKAP9-BRAF FUSION PROTEIN","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",6,"VAL A 124;ALA A 137;THR A 187;CYH A 190;PHE A 240;GLY A 253","H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);H8H A 401 (-4.3A);None","0.67A","3og7A-5vcxA:18.1","3og7A-5vcxA:25.72"],["3OG7_A_032A1_1","AKAP9-BRAF FUSION PROTEIN","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",6,"VAL A 124;ALA A 137;THR A 187;CYH A 190;PHE A 240;PHE A 252","H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);H8H A 401 (-4.3A);None","0.83A","3og7A-5vcxA:18.1","3og7A-5vcxA:25.72"],["3OHT_B_1N1B1000_1","P38A","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",5,"GLY A 117;VAL A 124;ALA A 137;LYS A 139;THR A 187","H8H A 401 ( 3.7A);H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-4.9A);H8H A 401 (-3.5A)","0.49A","3ohtB-5vcxA:18.0","3ohtB-5vcxA:24.94"],["3PYY_A_STIA3_1","V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",6,"LEU A 116;VAL A 124;ALA A 137;GLU A 157;THR A 187;GLY A 191","H8H A 401 (-3.7A);H8H A 401 (-4.7A);H8H A 401 (-3.3A);None;H8H A 401 (-3.5A);H8H A 401 (-4.4A)","0.75A","3pyyA-5vcxA:18.1","3pyyA-5vcxA:26.01"],["3PYY_B_STIB4_1","V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",6,"LEU A 116;VAL A 124;ALA A 137;GLU A 157;VAL A 171;THR A 187","H8H A 401 (-3.7A);H8H A 401 (-4.7A);H8H A 401 (-3.3A);None;None;H8H A 401 (-3.5A)","0.61A","3pyyB-5vcxA:18.0","3pyyB-5vcxA:26.01"],["4MXO_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",8,"LEU A 116;VAL A 124;ALA A 137;LYS A 139;GLU A 157;VAL A 171;THR A 187;ASP A 251","H8H A 401 (-3.7A);H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-4.9A);None;None;H8H A 401 (-3.5A);EDO A 402 ( 2.9A)","0.85A","4mxoA-5vcxA:19.7","4mxoA-5vcxA:26.57"],["4R7I_A_STIA1001_1","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",6,"VAL A 124;ALA A 137;GLU A 157;THR A 187;CYH A 190;GLY A 250","H8H A 401 (-4.7A);H8H A 401 (-3.3A);None;H8H A 401 (-3.5A);H8H A 401 (-4.3A);None","0.60A","4r7iA-5vcxA:22.7","4r7iA-5vcxA:28.34"],["4RZV_A_032A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",6,"ALA A 137;THR A 187;SER A 193;PHE A 240;GLY A 250;GLY A 253","H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 ( 4.4A);H8H A 401 (-4.3A);None;None","1.11A","4rzvA-5vcxA:5.4","4rzvA-5vcxA:26.10"],["4RZV_A_032A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",6,"ALA A 137;THR A 187;SER A 193;PHE A 240;GLY A 250;PHE A 252","H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 ( 4.4A);H8H A 401 (-4.3A);None;None","0.78A","4rzvA-5vcxA:5.4","4rzvA-5vcxA:26.10"],["4RZV_B_032B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",7,"ALA A 137;THR A 187;CYH A 190;SER A 193;PHE A 240;GLY A 250;GLY A 253","H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);H8H A 401 ( 4.4A);H8H A 401 (-4.3A);None;None","1.17A","4rzvB-5vcxA:17.4","4rzvB-5vcxA:26.10"],["4RZV_B_032B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",7,"ALA A 137;THR A 187;CYH A 190;SER A 193;PHE A 240;GLY A 250;PHE A 252","H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);H8H A 401 ( 4.4A);H8H A 401 (-4.3A);None;None","0.88A","4rzvB-5vcxA:17.4","4rzvB-5vcxA:26.10"],["4RZV_B_032B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",6,"VAL A 124;ALA A 137;LYS A 139;THR A 187;CYH A 190;GLY A 253","H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-4.9A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);None","1.11A","4rzvB-5vcxA:17.4","4rzvB-5vcxA:26.10"],["4RZV_B_032B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",7,"VAL A 124;ALA A 137;THR A 187;CYH A 190;SER A 193;PHE A 240;GLY A 253","H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);H8H A 401 ( 4.4A);H8H A 401 (-4.3A);None","0.96A","4rzvB-5vcxA:17.4","4rzvB-5vcxA:26.10"],["4RZV_B_032B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",7,"VAL A 124;ALA A 137;THR A 187;CYH A 190;SER A 193;PHE A 240;PHE A 252","H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);H8H A 401 ( 4.4A);H8H A 401 (-4.3A);None","0.91A","4rzvB-5vcxA:17.4","4rzvB-5vcxA:26.10"],["4UXQ_A_0LIA1752_1","FIBROBLAST GROWTH FACTOR RECEPTOR 4","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",5,"LEU A 116;ALA A 137;GLU A 157;LEU A 224;HIS A 231","H8H A 401 (-3.7A);H8H A 401 (-3.3A);None;None;None","0.59A","4uxqA-5vcxA:22.9","4uxqA-5vcxA:24.21"],["4XV2_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",7,"VAL A 124;ALA A 137;THR A 187;CYH A 190;PHE A 240;GLY A 250;ASP A 251","H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);H8H A 401 (-4.3A);None;EDO A 402 ( 2.9A)","0.76A","4xv2A-5vcxA:18.5","4xv2A-5vcxA:25.50"],["4XV2_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",7,"VAL A 124;ALA A 137;THR A 187;PHE A 240;GLY A 250;ASP A 251;PHE A 252","H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);None;EDO A 402 ( 2.9A);None","0.81A","4xv2A-5vcxA:18.5","4xv2A-5vcxA:25.50"],["4XV2_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",6,"ALA A 137;THR A 187;CYH A 190;PHE A 240;GLY A 250;ASP A 251","H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);H8H A 401 (-4.3A);None;EDO A 402 ( 2.9A)","0.67A","4xv2B-5vcxA:22.6","4xv2B-5vcxA:25.50"],["4XV2_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",6,"ALA A 137;THR A 187;PHE A 240;GLY A 250;ASP A 251;PHE A 252","H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);None;EDO A 402 ( 2.9A);None","0.65A","4xv2B-5vcxA:22.6","4xv2B-5vcxA:25.50"],["5CSW_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",6,"VAL A 124;ALA A 137;THR A 187;CYH A 190;PHE A 240;GLY A 250","H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);H8H A 401 (-4.3A);None","0.66A","5cswA-5vcxA:22.0","5cswA-5vcxA:24.63"],["5CSW_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",6,"VAL A 124;ALA A 137;THR A 187;PHE A 240;GLY A 250;PHE A 252","H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);None;None","0.84A","5cswA-5vcxA:22.0","5cswA-5vcxA:24.63"],["5CSW_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",6,"VAL A 124;ALA A 137;THR A 187;CYH A 190;PHE A 240;GLY A 250","H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);H8H A 401 (-4.3A);None","0.63A","5cswB-5vcxA:22.4","5cswB-5vcxA:24.63"],["5CSW_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",6,"VAL A 124;ALA A 137;THR A 187;PHE A 240;GLY A 250;PHE A 252","H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);None;None","0.83A","5cswB-5vcxA:22.4","5cswB-5vcxA:24.63"],["5H2U_D_1N1D504_1","PROTEIN-TYROSINE KINASE 6","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",7,"LEU A 116;VAL A 124;ALA A 137;THR A 187;LEU A 189;GLY A 250;ASP A 251","H8H A 401 (-3.7A);H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-3.5A);None;None;EDO A 402 ( 2.9A)","0.65A","5h2uD-5vcxA:17.1","5h2uD-5vcxA:25.73"],["5HI2_A_BAXA801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",7,"ALA A 137;GLU A 157;THR A 187;CYH A 190;LEU A 224;HIS A 231;GLY A 250","H8H A 401 (-3.3A);None;H8H A 401 (-3.5A);H8H A 401 (-4.3A);None;None;None","0.71A","5hi2A-5vcxA:22.3","5hi2A-5vcxA:26.01"],["5HI2_A_BAXA801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",7,"ALA A 137;LYS A 139;GLU A 157;THR A 187;CYH A 190;HIS A 231;GLY A 250","H8H A 401 (-3.3A);H8H A 401 (-4.9A);None;H8H A 401 (-3.5A);H8H A 401 (-4.3A);None;None","0.80A","5hi2A-5vcxA:22.3","5hi2A-5vcxA:26.01"],["5HIE_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",5,"VAL A 124;ALA A 137;THR A 187;PHE A 240;GLY A 250","H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);None","0.64A","5hieA-5vcxA:7.0","5hieA-5vcxA:27.51"],["5HIE_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",5,"VAL A 124;ALA A 137;THR A 187;PHE A 240;GLY A 250","H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);None","0.66A","5hieB-5vcxA:6.9","5hieB-5vcxA:27.51"],["5HIE_C_P06C801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",6,"GLY A 117;VAL A 124;ALA A 137;THR A 187;PHE A 240;GLY A 250","H8H A 401 ( 3.7A);H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);None","0.75A","5hieC-5vcxA:21.2","5hieC-5vcxA:27.51"],["5HIE_C_P06C801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",6,"VAL A 124;ALA A 137;THR A 187;PHE A 240;GLY A 250;ASP A 251","H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);None;EDO A 402 ( 2.9A)","0.81A","5hieC-5vcxA:21.2","5hieC-5vcxA:27.51"],["5HIE_D_P06D801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",5,"VAL A 124;ALA A 137;THR A 187;PHE A 240;GLY A 250","H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);None","0.65A","5hieD-5vcxA:21.0","5hieD-5vcxA:27.51"],["5IZJ_G_AZ1G2_1","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA;47P-AZ1-DAR-DAR","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",5,"GLY A 117;GLY A 119;SER A 120;VAL A 124;LYS A 139","H8H A 401 ( 3.7A);None;None;H8H A 401 (-4.7A);H8H A 401 (-4.9A)","0.80A","5izjA-5vcxA:24.3","5izjA-5vcxA:26.57"],["5J5X_B_AZ1B2_1","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA;47P-AZ1-DAL-DAR-DAR-DAR-DAR","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",5,"GLY A 117;GLY A 119;SER A 120;VAL A 124;LYS A 139","H8H A 401 ( 3.7A);None;None;H8H A 401 (-4.7A);H8H A 401 (-4.9A)","0.66A","5j5xA-5vcxA:24.1","5j5xA-5vcxA:26.57"],["5OWR_A_1N1A401_1","SERINE\/THREONINE-PROTEIN KINASE 10","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",4,"ALA A 137;GLU A 157;CYH A 190;ASP A 251","H8H A 401 (-3.3A);None;H8H A 401 (-4.3A);EDO A 402 ( 2.9A)","0.53A","5owrA-5vcxA:15.2","5owrA-5vcxA:27.05"],["5VC3_A_DB8A601_1","WEE1-LIKE PROTEIN KINASE","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",6,"ALA A 137;GLU A 157;CYH A 190;GLY A 191;PHE A 240;ASP A 251","H8H A 401 (-3.3A);None;H8H A 401 (-4.3A);H8H A 401 (-4.4A);H8H A 401 (-4.3A);EDO A 402 ( 2.9A)","0.97A","5vc3A-5vcxA:24.0","5vc3A-5vcxA:32.43"],["5VC3_A_DB8A601_2","WEE1-LIKE PROTEIN KINASE","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",4,"VAL A 124;LYS A 139;VAL A 171;ASN A 238","H8H A 401 (-4.7A);H8H A 401 (-4.9A);None;EDO A 402 (-3.9A)","0.37A","5vc3A-5vcxA:24.0","5vc3A-5vcxA:32.43"],["5VCV_A_1N1A404_1","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",12,"LEU A 116;ALA A 137;LYS A 139;GLU A 157;VAL A 171;LEU A 185;THR A 187;GLY A 191;PRO A 192;GLN A 196;PHE A 240;GLY A 250","H8H A 401 (-3.7A);H8H A 401 (-3.3A);H8H A 401 (-4.9A);None;None;H8H A 401 (-4.3A);H8H A 401 (-3.5A);H8H A 401 (-4.4A);H8H A 401 ( 4.1A);H8H A 401 ( 4.4A);H8H A 401 (-4.3A);None","0.59A","5vcvA-5vcxA:43.9","5vcvA-5vcxA:100.00"],["5VCV_A_1N1A404_2","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",5,"VAL A 124;HIS A 161;LEU A 189;CYH A 190;ASP A 251","H8H A 401 (-4.7A);None;None;H8H A 401 (-4.3A);EDO A 402 ( 2.9A)","0.50A","5vcvA-5vcxA:44.0","5vcvA-5vcxA:100.00"],["5VCY_A_DB8A401_1","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",12,"LEU A 116;VAL A 124;ALA A 137;LYS A 139;GLU A 157;LEU A 185;THR A 187;CYH A 190;GLY A 191;PRO A 192;GLN A 196;PHE A 240","H8H A 401 (-3.7A);H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-4.9A);None;H8H A 401 (-4.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);H8H A 401 (-4.4A);H8H A 401 ( 4.1A);H8H A 401 ( 4.4A);H8H A 401 (-4.3A)","0.53A","5vcyA-5vcxA:42.4","5vcyA-5vcxA:100.00"],["5VCY_A_DB8A401_2","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",4,"VAL A 171;LEU A 189;ASN A 238;ASP A 251","None;None;EDO A 402 (-3.9A);EDO A 402 ( 2.9A)","0.75A","5vcyA-5vcxA:42.4","5vcyA-5vcxA:100.00"],["5Y7Z_A_IREA401_0","CYCLIN-G-ASSOCIATED KINASE","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",7,"LEU A 116;VAL A 124;ALA A 137;LYS A 139;GLU A 157;LEU A 189;CYH A 190","H8H A 401 (-3.7A);H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-4.9A);None;None;H8H A 401 (-4.3A)","0.44A","5y7zA-5vcxA:23.4","5y7zA-5vcxA:14.00"],["5Y7Z_A_IREA401_0","CYCLIN-G-ASSOCIATED KINASE","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",7,"LEU A 116;VAL A 124;ALA A 137;LYS A 139;GLU A 157;LEU A 189;CYH A 190","H8H A 401 (-3.7A);H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-4.9A);None;None;H8H A 401 (-4.3A)","0.44A","5y7zA-5vcxA:23.4","5y7zA-5vcxA:26.30"],["5Y7Z_A_IREA401_0","CYCLIN-G-ASSOCIATED KINASE","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",7,"VAL A 124;ALA A 137;LYS A 139;GLU A 157;LEU A 189;CYH A 190;GLY A 191","H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-4.9A);None;None;H8H A 401 (-4.3A);H8H A 401 (-4.4A)","0.95A","5y7zA-5vcxA:23.4","5y7zA-5vcxA:14.00"],["5Y7Z_A_IREA401_0","CYCLIN-G-ASSOCIATED KINASE","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",7,"VAL A 124;ALA A 137;LYS A 139;GLU A 157;LEU A 189;CYH A 190;GLY A 191","H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-4.9A);None;None;H8H A 401 (-4.3A);H8H A 401 (-4.4A)","0.95A","5y7zA-5vcxA:23.4","5y7zA-5vcxA:26.30"],["5Y7Z_B_IREB401_0","CYCLIN-G-ASSOCIATED KINASE","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",8,"LEU A 116;ALA A 137;GLU A 157;LEU A 185;LEU A 189;CYH A 190;GLY A 191;ASP A 251","H8H A 401 (-3.7A);H8H A 401 (-3.3A);None;H8H A 401 (-4.3A);None;H8H A 401 (-4.3A);H8H A 401 (-4.4A);EDO A 402 ( 2.9A)","0.89A","5y7zB-5vcxA:23.5","5y7zB-5vcxA:14.00"],["5Y7Z_B_IREB401_0","CYCLIN-G-ASSOCIATED KINASE","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",8,"LEU A 116;ALA A 137;LYS A 139;GLU A 157;LEU A 185;LEU A 189;CYH A 190;GLY A 191","H8H A 401 (-3.7A);H8H A 401 (-3.3A);H8H A 401 (-4.9A);None;H8H A 401 (-4.3A);None;H8H A 401 (-4.3A);H8H A 401 (-4.4A)","0.99A","5y7zB-5vcxA:23.5","5y7zB-5vcxA:14.00"],["5Y80_A_IREA401_0","CYCLIN-G-ASSOCIATED KINASE","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",9,"LEU A 116;VAL A 124;ALA A 137;GLU A 157;THR A 187;LEU A 189;CYH A 190;GLY A 191;ASP A 251","H8H A 401 (-3.7A);H8H A 401 (-4.7A);H8H A 401 (-3.3A);None;H8H A 401 (-3.5A);None;H8H A 401 (-4.3A);H8H A 401 (-4.4A);EDO A 402 ( 2.9A)","0.82A","5y80A-5vcxA:22.7","5y80A-5vcxA:14.00"],["5Y80_A_IREA401_0","CYCLIN-G-ASSOCIATED KINASE","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",9,"LEU A 116;VAL A 124;ALA A 137;LYS A 139;GLU A 157;THR A 187;LEU A 189;CYH A 190;GLY A 191","H8H A 401 (-3.7A);H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-4.9A);None;H8H A 401 (-3.5A);None;H8H A 401 (-4.3A);H8H A 401 (-4.4A)","0.93A","5y80A-5vcxA:22.7","5y80A-5vcxA:14.00"],["5YW0_A_ACTA411_0","UNCHARACTERIZED PROTEIN KDOO","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",3,"LYS A 126;LEU A 135;ARG A 128","None","0.88A","5yw0A-5vcxA:undetectable","5yw0A-5vcxA:23.45"],["6HD6_B_STIB601_0","TYROSINE-PROTEIN KINASE ABL1","5vcx","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","Homo sapiens",7,"LEU A 116;VAL A 124;ALA A 137;LYS A 139;GLU A 157;VAL A 171;THR A 187","H8H A 401 (-3.7A);H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-4.9A);None;None;H8H A 401 (-3.5A)","0.71A","6hd6B-5vcxA:17.5","6hd6B-5vcxA:13.27"]]